The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus.

[1]  Kyoko Iwao-Koizumi,et al.  Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population , 2015, International journal of medical sciences.

[2]  S. Aliño,et al.  Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies , 2014, The Pharmacogenomics Journal.

[3]  Jian-jun Zhang,et al.  Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation , 2014, PloS one.

[4]  A. Åsberg,et al.  Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling , 2014, British journal of clinical pharmacology.

[5]  T. Matsui,et al.  Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short‐term remission in patients with ulcerative colitis treated with tacrolimus , 2014, Journal of gastroenterology and hepatology.

[6]  D. Hesselink,et al.  The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.

[7]  G. Koren,et al.  Tacrolimus-induced nephrotoxicity and genetic variability: a review. , 2012, Annals of transplantation.

[8]  G. Russ,et al.  Specialty practice series: Intrapatient variability with tacrolimus , 2012 .

[9]  J. George,et al.  Pharmacist-led lipid clinic for surgical patients with peripheral vascular disease , 2012 .

[10]  D. Ferrante,et al.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation , 2011, European Journal of Clinical Pharmacology.

[11]  M. Okuda,et al.  Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. , 2011, Clinical therapeutics.

[12]  Mamoru Watanabe,et al.  The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease , 2011, Journal of Gastroenterology.

[13]  K. Verbeke,et al.  Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients , 2010, Therapeutic drug monitoring.

[14]  Markus F. Neurath,et al.  New pathophysiological insights and modern treatment of IBD , 2010, Journal of Gastroenterology.

[15]  E. Lerut,et al.  Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  J. Wen,et al.  Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. , 2009, Transplantation proceedings.

[17]  B. Charpentier,et al.  Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. , 2008, Basic & clinical pharmacology & toxicology.

[18]  J. Paulauskis,et al.  Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First‐ and Third‐generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations , 2008, Clinical pharmacology and therapeutics.

[19]  G. Tenderich,et al.  No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  S. Uemoto,et al.  Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients , 2008, Pharmacogenetics and genomics.

[21]  E. Lerut,et al.  CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients , 2007, Clinical pharmacology and therapeutics.

[22]  A. Takagi,et al.  [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor]. , 2006, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[23]  T. Matsui,et al.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.

[24]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[25]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.